PMV Pharmaceuticals (PMVP) to Release Earnings on Friday

Key Points

• PMV Pharmaceuticals (NASDAQ:PMVP) will report Q1 2026 results before the market opens on Friday, May 8 at 9:30 AM ET, and analysts expect a loss of ($0.40) per share
• The stock trades around $1.39 with a market cap of about $74.1 million, a 52‑week range of $0.81–$1.88, and 50‑/200‑day moving averages near $1.41 and $1.31 respectively.
• Institutional investors hold roughly 90.2% of the shares with recent buying from Vanguard, Squarepoint and Geode, while analyst sentiment is mixed—one Strong Buy and one Sell, averaging a "Moderate Buy" rating.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect PMV Pharmaceuticals to post earnings of ($0.40) per share for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 9:30 AM ET.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its quarterly earnings data on Friday, March 6th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, analysts expect PMV Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PMV Pharmaceuticals Price Performance

NASDAQ:PMVP opened at $1.39 on Friday. The stock has a market cap of $74.13 million, a price-to-earnings ratio of -0.93 and a beta of 1.40. The company's 50 day moving average price is $1.41 and its 200-day moving average price is $1.31. PMV Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $1.88.

Institutional Trading of PMV Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of PMV Pharmaceuticals by 0.4% in the third quarter. Vanguard Group Inc. now owns 2,163,027 shares of the company's stock worth $3,028,000 after purchasing an additional 9,427 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of PMV Pharmaceuticals by 101.8% in the fourth quarter. Squarepoint Ops LLC now owns 26,502 shares of the company's stock valued at $33,000 after purchasing an additional 13,367 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of PMV Pharmaceuticals by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 446,140 shares of the company's stock valued at $558,000 after purchasing an additional 14,320 shares in the last quarter. Public Employees Retirement System of Ohio increased its position in PMV Pharmaceuticals by 349.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company's stock worth $34,000 after purchasing an additional 21,334 shares during the last quarter. Finally, Shay Capital LLC purchased a new stake in PMV Pharmaceuticals during the second quarter valued at $26,000. Institutional investors own 90.20% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Evercore raised PMV Pharmaceuticals to a "strong-buy" rating in a research report on Monday, April 13th. Weiss Ratings upgraded PMV Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy".

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.